Robert Friesen

Title: Innovations in Influenza Vaccination by Robert Friesen

Introduction

Robert Friesen is an accomplished inventor based in Wassenaar, Netherlands. He has made significant contributions to the field of immunology, particularly in the development of innovative vaccines against influenza. His work focuses on utilizing recombinant adeno-associated viruses to enhance vaccine efficacy.

Latest Patents

Friesen holds a patent for an AAV-mediated influenza vaccine. This non-replicating recombinant adeno-associated virus (rAAV) features an AAV capsid that packages a vector genome. The genome includes AAV inverted terminal repeat sequences and at least one nucleic acid sequence encoding four different immunoglobulin regions, designated as (a), (b), (c), and (d). The rAAV-expressed immunoglobulins are designed to provide passive immunization against both influenza A and influenza B. The patent also describes compositions containing the rAAV and methods for vaccinating patients against influenza.

Career Highlights

Throughout his career, Robert Friesen has worked with prestigious organizations, including the University of Pennsylvania and Janssen Biotech, Inc. His experience in these institutions has allowed him to collaborate with leading experts in the field of vaccine development.

Collaborations

Friesen has collaborated with notable colleagues, including Maria P Limberis and Anna P Tretiakova. Their combined expertise has contributed to advancements in the research and development of effective influenza vaccines.

Conclusion

Robert Friesen's innovative work in the field of influenza vaccination exemplifies the importance of research and collaboration in developing effective medical solutions. His contributions continue to impact public health positively.